

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Comment received in draft scope consultation:

'Bladder cancer might be more common in men, however women are much less likely to receive a timely diagnosis (Zhou, Y.; Walter, F.M.; Singh, H.; Hamilton, W.; Abel, G.A.; Lyratzopoulos, G. Prolonged Diagnostic Intervals as Marker of Missed Diagnostic Opportunities in Bladder and Kidney Cancer Patients with Alarm Features: A Longitudinal Linked Data Study. *Cancers* 2021, 13, 156). Women with bladder cancer also have worse outcomes compared to men. Women tend to present with advanced stage, experience differences in quality of life following treatment, and suffer worse cancer-specific mortality (Hart ST, Woods ME, Quek ML. Gender disparities in bladder cancer management. *Urology Times*, February 20, 2019, Volume: 47, Issue: 2)'

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Differences in incidence of a disease cannot be addressed in a technology appraisal. Stakeholders can submit evidence on differing diagnosis timeliness, outcomes and quality of life between sexes.

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor

Issue date: April 2021

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Jasdeep Hayre.....

Date: 21 April 2021